the aid library

LIST OPTIONS

Filter

7020

Developing drinking-water quality regulations and standards: general guidance with a special focus on countries with limited resources

World Health Organization (WHO) (2018) CC

Drinking-water quality regulations and standards developed or revised in accordance with this guidance will reflect the best practices identified in the WHO Guidelines for Drinking-water Quality to most effectively protect public health. Moreover, the regulations and standards will consider local ne... more

Download (345)

View PDF (413)

National surgical, obstetric and anesthesia strategic plan (NSOASP) Year 2017-2021

Ministry of Health, Zambia (2017) CC

Download (1324)

View PDF (3385)

Oral Cholera Vaccine Use in Complex Emergencies: What next?

World Health Organization (2005)

Download (1401)

View PDF (3073)

Epidemic diarrhoeal disease preparedness and response. training and practice. Facilitator's guide

World Health Organization (2014)

Accessed November 2014

Download (953)

View PDF (1568)

Worldwide country situation analysis: response to antimicrobial resistance

World Health Organization (2015) C_WHO

A survey was conducted in countries in all six WHO regions and focused on the building blocks that are considered prerequisites to combat antimicrobial resistance: a comprehensive national plan, laboratory capacity to undertake surveillance for resistant microorganisms, access to safe, effective ant... more

Download (423)

View PDF (853)

First Bangladesh National Tuberculosis Drug Resistance Survey 2010-2011

Ministry of Health and Family Welfare, Directorate-General of Health Services, Mycobacterial Disease Control, National Tuberculosis Control Programme (2013) C_WHO

Download (299)

View PDF (316)

National Action Plan of the Islamic Republic of Iran for combating antimicrobial resistance

Ministry of Health and Medical Education Iran (2016) C_WHO

Antimicrobial resistance is one of the most important threats to the health worldwide. Antimicrobial resistance or drug resistance is the reduction of the pharmaceutical effects of a drug against a disease or reduction of its effectiveness in improving the clinical signs of a disease. Antimicrobial ... more

Download (451)

View PDF (450)

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WH... more

External Link

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

Download (782)

View PDF (1412)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (1494)

View PDF (1787)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (467)

View PDF (693)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (1068)

View PDF (1335)

WHO recommendations for prevention and treatment of maternal peripartum infections

World Health Organization WHO (2015) C_WHO

Download (495)

View PDF (806)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (346)

View PDF (531)

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов

Delphine Sculier, Haileyesus Getahun, Reuben Granich World Health Organization, TB HIV working group, Stop TB Partnership (2011) C_WHO

Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот... more

Download (1502)

View PDF (1200)

Standards for Prosthetics and Orthotics Service Provision. 2015-2017 work plan

Department of Essential Medicines and Health Products (EMP) and NVI World Health Organisation (WHO); USAID; ISPO (2015) C_WHO

Download (2430)

View PDF (2920)

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended

World Health Organization WHO WHO (2012) C_WHO

Guidance for health workers

Download (281)

View PDF (395)

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

Download (2050)

View PDF (1513)

India: National Programme for the Control of Blindness Guidelines

National Rural Health Mission (2009) C1

Guidelines for State Health Society and District Health Society

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer) recommended

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended